secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEUROCRINE BIOSCIENCES INC (NBIX)
CIK:        0000914475
Form:       8-K
Filed at:   2024-02-07T23:59:59+00:00
Accession:  0000914475-24-000033
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Neurocrine Q4 INGREZZA sales $500M (+25% YoY); FY 2024 guidance $2.1-$2.2B
--------------------------------------------------------------------------

- Q4 GAAP net income $147.7M ($1.44 diluted EPS) vs $89M ($0.88) in Q4 2022; non-GAAP EPS $1.54.
- Full-year 2023 INGREZZA net product sales $1.84B (+29% YoY); total revenue $1.89B.
- FY 2024 INGREZZA sales guidance $2.1–$2.2B; GAAP R&D $645–$675M, SG&A $930–$950M.
- Patent litigation resolved; generic INGREZZA entry no earlier than March 2038.
- Crinecerfont FDA submission for congenital adrenal hyperplasia expected Q2 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/914475/000091447524000033/0000914475-24-000033-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/914475/000091447524000033/nbix-20240207.htm
  HTML page:      https://secwatch.observer/filing/0000914475-24-000033

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer